Zinc levels in serum during subcutaneous interleukin-2 immunotherapy of cancer.
Lissoni
P
P
Arosio
V
V
Mocchegiani
E
E
Fabris
N
N
Barni
S
S
Pierpaoli
W
W
Tancini
G
G
D000328:Adult; D000368:Aged; D015415:Biomarkers; D002292:Carcinoma, Renal Cell / Q000097:blood* / Q000556:secondary / Q000628:therapy; D002940:Circadian Rhythm / Q000187:drug effects; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D007680:Kidney Neoplasms / Q000097:blood* / Q000628:therapy; D008297:Male; D008550:Melatonin / Q000378:metabolism; D008875:Middle Aged; D010870:Pineal Gland / Q000187:drug effects / Q000378:metabolism; D015032:Zinc / Q000097:blood* / Q000172:deficiency
D015415:Biomarkers; D007155:Immunologic Factors; D007376:Interleukin-2; D015032:Zinc; D008550:Melatonin